Anna Caroli

List of Publications by Year
in descending order

62 papers	4,014 citations	101543 36 h-index	118850 62 g-index
66 all docs	66 docs citations	66 times ranked	5627 citing authors

#	Article	IF	Citations
1	ConsensusâEBased Technical Recommendations for Clinical Translation of Renal Phase Contrast <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2022, 55, 323-335.	3.4	22
2	The use of AVF.SIM system for the surgical planning of arteriovenous fistulae in routine clinical practice. Journal of Vascular Access, 2022, , 112972982110626.	0.9	1
3	Diffusion-Weighted Magnetic Resonance Imaging: Clinical Potential and Applications. Journal of Clinical Medicine, 2022, 11, 3339.	2.4	3
4	Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department. European Radiology, 2021, 31, 1999-2012.	4.5	86
5	Cerebral superb microvascular imaging in preterm neonates: in vivo evaluation of thalamic, striatal, and extrastriatal angioarchitecture. Neuroradiology, 2021, 63, 1103-1112.	2.2	12
6	Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients. European Journal of Radiology, 2021, 138, 109676.	2.6	39
7	Basic principles and new advances in kidney imaging. Kidney International, 2021, 100, 1001-1011.	5.2	25
8	Renal Diffusion-Weighted Imaging (DWI) for Apparent Diffusion Coefficient (ADC), Intravoxel Incoherent Motion (IVIM), and Diffusion Tensor Imaging (DTI): Basic Concepts. Methods in Molecular Biology, 2021, 2216, 187-204.	0.9	5
9	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	4.5	53
10	Phase-contrast magnetic resonance imaging to assess renal perfusion: a systematic review and statement paper. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 3-21.	2.0	26
11	Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosis. Kidney International, 2020, 97, 442-444.	5.2	11
12	Technical recommendations for clinical translation of renal MRI: a consensus project of the Cooperation in Science and Technology Action PARENCHIMA. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 131-140.	2.0	44
13	Consensus-based technical recommendations for clinical translation of renal diffusion-weighted MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 177-195.	2.0	61
14	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Medicine, 2020, 2, 804-809.	2.0	2
15	Prognostic value of Alzheimerâ€™s biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
16	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	8.4	42
17	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. Radiology, 2019, 290, 769-782.	7.3	69
18	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.7	91

#	Article	IF	Citations
19	Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrology Dialysis Transplantation, 2018, 33, ii29-ii40.	0.7	111
20	Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii1-ii3.	0.7	32
21	Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper. Nephrology Dialysis Transplantation, 2018, 33, ii41-ii50.	0.7	75
22	Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review. Nephrology Dialysis Transplantation, 2018, 33, ii22-ii28.	0.7	88
23	Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease. Scientific Reports, 2017, 7, 2049.	3.3	115
24	Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS ONE, 2017, 12, e0178488.	2.5	40
25	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	3.1	53
26	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 785-794.	4.5	35
27	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
28	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. Neurobiology of Aging, 2015, 36, 776-788.	3.1	25
29	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.1	122
30	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Disease and Associated Disorders, 2015, 29, 101-109.	1.3	14
31	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage: Clinical, 2014, 6, 445-454.	2.7	172
32	A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. Neuroinformatics, 2014, 12, 575-593.	2.8	240
33	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
34	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimerâ€™s disease. Clinical and Translational Imaging, 2013, 1, 279-288.	2.1	3
35	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. Gastroenterology, 2013, 145, 357-365.e2.	1.3	76
36	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	13.7	218

#	Article	IF	Citations
37	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
38	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	5.0	108
39	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.1	161
40	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney International, 2013, 84, 1237-1245.	5.2	67
41	Summary Metrics to Assess Alzheimer Diseaseâ€“Related Hypometabolic Pattern with ¹⁸F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	5.0	79
42	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	3.1	108
43	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. American Journal of Pathology, 2011, 179, 619-627.	3.8	19
44	Clinical Study Protocol for the ARCH Project Computational Modeling for Improvement of Outcome after Vascular Access Creation. Journal of Vascular Access, 2011, 12, 369-376.	0.9	23
45	Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage. Journal of Alzheimer's Disease, 2011, 26, 159-199.	2.6	120
46	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	6.4	95
47	The new Alzheimerâ€™s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	3.6	44
48	Metabolic Compensation and Depression in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2010, 29, 37-45.	1.5	18
49	Reducing Polycystic Liver Volume in ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 783-789.	4.5	126
50	Sirolimus Therapy to Halt the Progression of ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1031-1040.	6.1	157
51	Clinical and medial temporal features in a family with mood disorders. Neuroscience Letters, 2010, 468, 93-97.	2.1	23
52	Functional compensation in incipient Alzheimer's disease. Neurobiology of Aging, 2010, 31, 387-397.	3.1	28
53	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiology of Aging, 2010, 31, 1263-1274.	3.1	126
54	In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology, 2009, 72, 1504-1511.	1.1	87

#	Article	IF	Citations
55	Quantitative evaluation of Alzheimerâ€™s disease. Expert Review of Medical Devices, 2009, 6, 569-588.	2.8	14
56	Relating one-year cognitive change in mild cognitive impairment to baseline MRI features. NeuroImage, 2009, 47, 1363-1370.	4.2	90
57	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	2.6	42
58	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	3.6	54
59	MRI-Based Automated Computer Classification of Probable AD Versus Normal Controls. IEEE Transactions on Medical Imaging, 2008, 27, 509-520.	8.9	133
60	Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment. Journal of Neurology, 2007, 254, 1000-1008.	3.6	36
61	Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. Journal of Neurology, 2007, 254, 1698-1707.	3.6	81
62	Structural brain imaging in patients with cognitive impairment in the year 2015. Future Neurology, 2006, 1, 77-86.	0.5	2